Durability Results of Treatment with Brentuximab Vedotin in Combination with Nivolumab in Patient with Relapsed or Refractory Hodgkin Lymphoma
Hodgkin’s lymphoma (HL) is a disease that represents approximately 10% of lymphomas with bimodal age distribution. It is curable in approximately 75 percent of patients worldwide. ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) was originally developed for patients with disease r...
| Main Authors: | , , , , |
|---|---|
| Published: |
Digital Commons @ East Tennessee State University
2020
|
| Subjects: | |
| Online Access: | https://dc.etsu.edu/asrf/2020/presentations/24 |